AVXL - CIK 0001314052
The table below shows ANAVEX LIFE SCIENCES CORP.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q4 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $4.66M | $9.96M | $9.89M | $10.45M | $11.81M | $9.73M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $2.13M |
| $4.50M |
| $2.62M |
| $3.15M |
| $2.79M |
| $2.90M |
| Operating income | -$6.78M | -$14.46M | -$12.51M | -$13.59M | -$14.60M | -$12.62M |
| Income tax | $18.00K | - | - | - | - | - |
| Net income | -$5.68M | -$13.24M | -$11.20M | -$12.11M | -$12.21M | -$10.55M |
| EPS (diluted) | -$0.06 | -$0.16 | -$0.13 | -$0.14 | -$0.14 | -$0.13 |